Innovent's Clinical Data Presentation of IBI310 & Sintilimab

Sunday, 2 June 2024, 22:52

In a recent event, Innovent showcased the results of a Phase 1b study that evaluated IBI310 and Sintilimab in combination. The study focused on the neoadjuvant treatment approach and showcased promising outcomes. The presentation highlighted the effectiveness of the Anti-CTLA-4 Monoclonal Antibody, IBI310, in conjunction with Sintilimab, offering new insights for future treatments in this space.

https://store.livarava.com/3bef3065-214c-11ef-a3f9-9d5fa15a64d8.jpg — Innovent's Clinical Data Presentation of IBI310 & Sintilimab

Innovent Delivers Clinical Presentation

Innovent recently presented the clinical data showcasing the results of a Phase 1b study evaluating IBI310 and Sintilimab together. The study focused on neoadjuvant treatment and highlighted promising outcomes with the combination therapy. The event emphasized the effectiveness of IBI310, an Anti-CTLA-4 Monoclonal Antibody, when used alongside Sintilimab.

This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.